Insilico Medicine
AI for Accelerated Drug Discovery
Cambridge, Massachusetts, Hong Kong
Global clinical-stage biotechnology company powered by generative AI focused on drug discovery.
How We Help
Problem Statement
The high time and cost associated with traditional drug discovery and development processes.
Core Technology
generative AI
Key Differentiators
End-to-End Generative AI Platform (Pharma.AI covers entire workflow); Speed and Efficiency (reduces preclinical discovery timelines to 12-18 months, drugs to Phase I in under 30 months); First AI-Discovered and AI-Designed Drug in Clinical Trials (for idiopathic pulmonary fibrosis, currently in Phase II); Diversified Pipeline (over 30 assets, 10 IND clearances); Strategic Partnerships and Licensing (high-value out-licensing and collaborations); Pioneering AI Techniques (Alex Zhavoronkov pioneered GANs and RL for molecular structure generation, developing autonomous AI agent PandaClaw).
Clinical Focus
Cancer, fibrosis (idiopathic pulmonary fibrosis), immunity, central nervous system (CNS) diseases, infectious diseases, autoimmune diseases, aging-related diseases, pain, obesity, muscle wasting
Target Customers
Pharmaceutical companies, biotech companies, academic institutions
Product Stage
GA
Company Info
- Business Model
- B2B, software licensing, therapeutic out-licensing
- Founded
- 2014
- Total Funding
- 1,050,000,000
- Website
- www.insilico.com/
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
First AI-discovered and AI-designed drug for idiopathic pulmonary fibrosis in Phase II clinical trials; achieved 10 IND clearances for pipeline assets.
MedStartr Index Score
?What do you think of Insilico Medicine?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.